Patent · US Active

Method to treat sickle cell disease

US8178509B2 · kind B2 · utility

0Cited by

85References

11Claims

0Family size

Assignee

University of Virginia Patent Foundation · US

Inventors

Joel M. Linden · Charlottesville, US
Kori Wallace · Charlottesville, US
Robert Alan Figler · Earlysville, US
Jayson M. Rieger · Charlottesville, US

Key dates

Filing date	Feb 9, 2007
Grant date	May 15, 2012
Priority date	—
Expiry date	Aug 30, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a therapeutic method for treating an inflammatory response caused by a sickle cell crisis, comprising administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor (e.g., rolipram).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.